Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics


Amy Shapiro, MD
Medical Director
Indiana Hemophilia and Thrombosis Center
Indianapolis, IN
Maya Bloomberg, MSN, APRN
Hematology Nurse Practitioner
University of Miami Hemophilia Treatment Center
Miami, FL
Mark W. Skinner, JD
President and CEO, Institute for Policy Advancement Ltd
Washington, DC
Assistant Professor
Department of Health Research Methods, Evidence and Impact
McMaster University
Hamilton, Ontario
Allison P. Wheeler, MD, MSCI
Associate Professor
Department of Pathology, Transfusion Medicine and Coagulation
Department of Pediatrics, Division of Pediatric Hematology
Director, Vanderbilt Benign Hematology Research Program
Vanderbilt University School of Medicine
Nashville, TN

Statement of Need

The treatment landscape for hemophilia A and B is expanding with strategies and therapies to optimize efficacy, provide durable hemostasis restoration, and improve safety. These contemporary approaches to care have also led to new pathways and assays for clinical and laboratory monitoring.

In this CME Outfitters Webcast, an interdisciplinary faculty, including a renowned patient advocate who has lived with hemophilia for many years, discuss the impact of key advances in treatment and monitoring on quality of care and outcomes. A focused segment on shared decision making (SDM) keeps the conversation grounded in counseling and collaboration and includes both clinician and patient perspectives.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess the clinical efficacy, durability in restoring hemostasis, and safety of anti-TFPIs and FVIII mimetics for the management of hemophilia
  • Develop a clinical and laboratory monitoring plan of the hemostatic status in patients receiving anti-TFPIs and FVIII mimetics
  • Implement SDM strategies to engage patients/caregivers with hemophilia in their treatment plan

Financial Support

Supported by an educational grant from Novo Nordisk, Inc.

Target Audience

Hematologists, hematologist/oncologists, nurse practitioners (NPs), physician associates (PAs), and other clinicians involved in the care of patients with hemophilia.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

PAs (AAPA) 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 04/15/2025. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Shapiro reports the following financial relationships:

Advisory Board: Be Biopharma; CSL Behring; Genentech, Inc./Roche; Novo Nordisk; Pfizer Inc.; Sanofi-Genzyme/Bioverativ Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Consultant: Kedrion Biopharma Inc. and Novo Nordisk
Research Support: Genentech, Inc./Roche; Kedrion Biopharma Inc.; Novo Nordisk; Pfizer Inc.; and Sanofi-Genzyme
Speakers Bureau: Genentech, Inc./Roche; Kedrion Biopharma Inc.; and Sanofi-Genzyme

Ms. Bloomberg reports the following financial relationships:

Advisory Board: Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and Takeda
Speakers Bureau: Bayer; Genentech, Inc.; Novo Nordisk; and Sanofi

Mr. Skinner reports the following financial relationships:

Advisory Board/Governance Boards: Blue Cross Blue Shield MAP; Institute for Clinical and Economic Review (ICER); National Organization for Rare Disorders, Inc. (NORD); Pfizer inc. (DSMB); Spark Therapeutics, Inc. (DSMB); and World Federation of Hemophilia USA (WFH USA)
Consultant: National Bleeding Disorders Foundation (NBDF)
Research Support: Mr. Skinner’s institution received research support for the PROBE Study and core outcomes studies as part of independent investigator-initiated research projects: Band Therapeutics, LLC; Bayer; BioMarin; CSL; Novo Nordisk; Roche/Genentech, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Vega Therapeutics Inc.

Dr. Wheeler reports the following financial relationships:

Advisory Board: Bayer; CSL Behring; Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and Vega Therapeutics Inc.
Research Support: Octapharma Plasma


The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Warren Beckman (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics
Event Date: 04/15/2024 at 12:00 am EST